Smith & Nephew plc
SNNUF
Other OTC15.10
USD
- -
- -
CIK
0000845982
ISIN
GB0009223206
Return %
Stock
S&P500
1Y
-1.82
20.29
3Y
2.51
67.23
5Y
-30.83
71.25
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Deepak S. Nath
- Full Time Employees
- 17,349
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Building 5 Watford United Kingdom WD18 8YE
- IPO Date
- Apr 21, 2009
- CIK
- 0000845982
- Website
- smith-nephew.com
- Similar Companies
- Business
- Smith & Nephew plc is a global medical technology company specializing in the development, manufacture, marketing, and sale of advanced medical devices focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates primarily through three global business segments: Advanced Wound Management, Sports Medicine & ENT, and Orthopaedics. Its core products include advanced wound dressings and negative pressure wound therapy systems for wound management; joint replacement devices, bone cement, and fixation products for orthopedic reconstruction; and arthroscopy tools and soft tissue repair solutions for sports medicine. The company also provides medical education, service programs, and digital ordering solutions such as its FORMEO web-based platform aimed at healthcare professionals. Smith & Nephew serves a broad international market with operations in over 100 countries. Founded in 1856 and headquartered in Watford, England, Smith & Nephew maintains major regional bases in the United States including facilities in Andover, Massachusetts for Sports Medicine & ENT, and Memphis, Tennessee for Orthopaedics. Recent major changes include the acquisition of the orthopedic extremity business from Integra in 2021, expanding its portfolio in a high-growth segment, and continued strategic focus on robotic-assisted surgery with prior acquisitions such as Blue Belt Technologies and the orthopedic joint reconstruction business unit from Brainlab. In 2025, Smith & Nephew has pursued operational improvements under a 12-point plan that has driven revenue growth and margin expansion, with raised free cash flow guidance to approximately $750 million. The company continues to invest in sustainable growth strategies, including the development of new manufacturing and R&D facilities in Melton, UK, while retaining select operations at its historic Hull site. Leadership changes include the appointment of Dr. Deepak Nath as CEO in 2022. Smith & Nephew remains committed to innovation in advanced wound care and orthopedic solutions and is preparing for a Capital Markets Day in December 2025 to outline its next phase of growth strategy. The company navigates challenges such as pricing pressures and tariffs while optimizing product portfolio sustainability, including selective market exits where profitability is limited. Smith & Nephew's extensive product range includes advanced wound management solutions like the PICO negative pressure wound therapy system, sports medicine devices including arthroscopy and ligament repair products, and orthopaedic reconstruction implants for hip, knee, and extremities, supported by digital and clinical service offerings. These integrated offerings target hospitals, outpatient surgical centers, and healthcare providers globally, reinforcing the company's position as a leader in medical technology innovation. This profile reflects Smith & Nephew's evolution as a portfolio medical technology company dedicated to improving patient outcomes through advanced wound treatment, minimally invasive surgery, and orthopedic reconstruction options on a global scale.